GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evogene Ltd (XTAE:EVGN) » Definitions » 3-Year RORE %

Evogene (XTAE:EVGN) 3-Year RORE % : -12.01% (As of Jun. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Evogene 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Evogene's 3-Year RORE % for the quarter that ended in Jun. 2024 was -12.01%.

The industry rank for Evogene's 3-Year RORE % or its related term are showing as below:

XTAE:EVGN's 3-Year RORE % is ranked worse than
53.87% of 1370 companies
in the Biotechnology industry
Industry Median: -9.245 vs XTAE:EVGN: -12.01

Evogene 3-Year RORE % Historical Data

The historical data trend for Evogene's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evogene 3-Year RORE % Chart

Evogene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.27 - -0.90 -8.37 40.06

Evogene Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.87 34.96 40.06 38.11 -12.01

Competitive Comparison of Evogene's 3-Year RORE %

For the Biotechnology subindustry, Evogene's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evogene's 3-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evogene's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Evogene's 3-Year RORE % falls into.



Evogene 3-Year RORE % Calculation

Evogene's 3-Year RORE % for the quarter that ended in Jun. 2024 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -14.7--29.25 )/( -121.197-0 )
=14.55/-121.197
=-12.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2024 and 3-year before.


Evogene  (XTAE:EVGN) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Evogene 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Evogene's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Evogene Business Description

Traded in Other Exchanges
Address
13 Gad Feinstein Street, Park Rehovot, P.O. Box 4173, Ness Ziona, Rehovot, ISR, 7414002
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment followed by Industry.